Sheng Yuze, Yu Qin, Huang Yanping, Zhu Quangang, Chen Zhongjian, Wu Wei, Yi Tao, Lu Yi
Key Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai 201203, China.
Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Pharmaceutics. 2023 Apr 26;15(5):1341. doi: 10.3390/pharmaceutics15051341.
Nanocrystals (NCs) have the potential to enhance the oral bioavailability of Class IV drugs in the Biopharmaceutical Classification System (BCS) due to the absorption of the intact crystals. The performance is compromised by the dissolution of NCs. Drug NCs have recently been adopted as solid emulsifiers to prepare nanocrystal self-stabilized Pickering emulsions (NCSSPEs). They are advantageous in high drug loading and low side effects due to the specific drug loading mode and the absence of chemical surfactants. More importantly, NCSSPEs may further enhance the oral bioavailability of drug NCs by impeding their dissolution. This is especially true for BCS IV drugs. In this study, curcumin (CUR), a typical BCS IV drug, was adopted to prepare CUR-NCs stabilized Pickering emulsions using either indigestible (isopropyl palmitate, IPP) or digestible (soybean oil, SO) oils, i.e., IPP-PEs and SO-PEs. The optimized formulations were spheric with CUR-NCs adsorbed on the water/oil interface. The CUR concentration in the formulation reached 20 mg/mL, which was far beyond the solubility of CUR in IPP (158.06 ± 3.44 μg/g) or SO (124.19 ± 2.40 μg/g). Moreover, the Pickering emulsions enhanced the oral bioavailability of CUR-NCs, being 172.85% for IPP-PEs and 152.07% for SO-PEs. The digestibility of the oil phase affected the amounts of CUR-NCs that remained intact in lipolysis and, thus, the oral bioavailability. In conclusion, converting NCs into Pickering emulsions provides a novel strategy to enhance the oral bioavailability of CUR and BCS IV drugs.
由于完整晶体的吸收,纳米晶体(NCs)有潜力提高生物药剂学分类系统(BCS)中IV类药物的口服生物利用度。然而,NCs的溶解会影响其性能。近年来,药物纳米晶体已被用作固体乳化剂来制备纳米晶体自稳定Pickering乳液(NCSSPEs)。由于其特定的载药模式和不含化学表面活性剂,它们具有高载药量和低副作用的优点。更重要的是,NCSSPEs可能通过阻止药物纳米晶体的溶解进一步提高其口服生物利用度。对于BCS IV类药物尤其如此。在本研究中,采用典型的BCS IV类药物姜黄素(CUR),使用难消化的(棕榈酸异丙酯,IPP)或可消化的(大豆油,SO)油制备CUR-NCs稳定的Pickering乳液,即IPP-PEs和SO-PEs。优化后的制剂呈球形,CUR-NCs吸附在水/油界面上。制剂中CUR的浓度达到20 mg/mL,远远超过CUR在IPP(158.06±3.44μg/g)或SO(124.19±2.40μg/g)中的溶解度。此外,Pickering乳液提高了CUR-NCs的口服生物利用度,IPP-PEs为172.85%,SO-PEs为152.07%。油相的消化率影响了脂解过程中保持完整的CUR-NCs的量,从而影响了口服生物利用度。总之,将纳米晶体转化为Pickering乳液为提高CUR和BCS IV类药物的口服生物利用度提供了一种新策略。